Literature DB >> 20386456

The mechanism of the negative chronotropic and dromotropic actions of adenosine 5'-triphosphate in the heart: an update.

Amir Pelleg1, Bernard Belhassen.   

Abstract

Adenosine 5'-triphosphate (ATP) plays a critical role in intracellular metabolism and energetics. Extracellular ATP is rapidly degraded to adenosine by ectoenzymes. Both ATP and adenosine suppress cardiac pacemakers' automaticity and atrioventricular nodal conduction, albeit via the different mechanism of actions. This historical update summarizes the current knowledge regarding the negative chronotropic and dromotropic actions of ATP and discusses the clinical implications regarding the utility of ATP as a diagnostic and therapeutic agent in the management of neutrally mediated syncope and paroxysmal supra ventricular tachycardia.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20386456     DOI： 10.1097/FJC.0b013e3181e0f8b2

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN： 0160-2446            Impact factor:   3.105


  8 in total

Review 1.  Cardiac purinergic signalling in health and disease.

Authors:  Geoffrey Burnstock; Amir Pelleg
Journal:  Purinergic Signal       Date:  2014-12-20       Impact factor: 3.765

2.  ATPace™: injectable adenosine 5'-triphosphate : Diagnostic and therapeutic indications.

Authors:  Amir Pelleg; Steven P Kutalek; Daniel Flammang; David Benditt
Journal:  Purinergic Signal       Date:  2011-11-06       Impact factor: 3.765

Review 3.  Adenosine 5'-triphosphate's role in bradycardia and syncope associated with pulmonary embolism.

Authors:  Amir Pelleg; Edward S Schulman; Peter J Barnes
Journal:  Respir Res       Date:  2018-07-28

4.  The Ionotropic P2X4 Receptor has Unique Properties in the Heart by Mediating the Negative Chronotropic Effect of ATP While Increasing the Ventricular Inotropy.

Authors:  Bruno Bragança; Sílvia Nogueira-Marques; Fátima Ferreirinha; Ana Patrícia Fontes-Sousa; Paulo Correia-de-Sá
Journal:  Front Pharmacol       Date:  2019-09-24       Impact factor: 5.810

5.  Serious bradycardia and remdesivir for coronavirus 2019 (COVID-19): a new safety concerns.

Authors:  Anthony Touafchia; Haleh Bagheri; Didier Carrié; Geneviève Durrieu; Agnès Sommet; Laurent Chouchana; François Montastruc
Journal:  Clin Microbiol Infect       Date:  2021-02-27       Impact factor: 8.067

6.  Clinical Characteristics and Implications of Bradycardia in COVID-19 Patients Treated with Remdesivir: A Single-Center Retrospective Cohort Study.

Authors:  Ariyon Schreiber; Justin S Bauzon; Kavita Batra; Salman Mohammed; Kevin Lee; Nazanin Houshmand; Uyen Pham; Celica Cosme; Kim Inciong; Omar Al-Taweel; Keaton Nasser; Jibran Rana; Chris Sossou; Ariel Go; Dalia Hawwass; Jimmy Diep; Chowdhury H Ahsan
Journal:  Clin Drug Investig       Date:  2022-08-17       Impact factor: 3.580

7.  P2×7 purinergic signaling in dilated cardiomyopathy induced by auto-immunity against muscarinic M2 receptors: autoantibody levels, heart functionality and cytokine expression.

Authors:  Camila Guerra Martinez; Daniel Zamith-Miranda; Marcia Gracindo da Silva; Karla Consort Ribeiro; Izaíra Trincani Brandão; Celio Lopes Silva; Bruno Lourenço Diaz; Maria Bellio; Pedro Muanis Persechini; Eleonora Kurtenbach
Journal:  Sci Rep       Date:  2015-11-23       Impact factor: 4.379

8.  Remdesivir therapy associated with Bradycardia in SARS-CoV2.

Authors:  Sabina Kumar; Christina Arcuri; Sumanta Chaudhuri; Rahul Gupta; Mahendra Aseri; Pranav Barve; Shivang Shah
Journal:  Clin Cardiol       Date:  2021-07-28       Impact factor: 3.287
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.